慢性髓细胞白血病化疗的回顾及进展

Systemic review on progress of drug therapy for chronic myelogenous leukemia

慢性髓细胞白血病(CML)是一种起源于多能造血干细胞的恶性克隆性疾病,随着对该疾病发病机制研究的进一步深入,临床治疗药物已从细胞毒化疗药物进展到针对该疾病致病基因的靶向治疗,临床预后改善显著。本文简要概述近一个世纪以来临床用于CML治疗的主要药物。

Chronic myelogenous leukemia （CML） is a myeloproliferative disorder arising from a specific genetic mutation. CML is distinguished by the presence of a reciprocal translocation between chromosomes 9 and 22. As a result of the translocation, a fusion gene called the bcr-abl gene is created, encoding a chimeric bcr-abl protein with a deregulated tyrosine kinase activity. In the past, CML was limited to treatment with standard cytoreductive therapies. These therapies provide temporary disease control, but don＇t alter progression to advanced disease, Current development of therapeutic agents targeting bcr-abl has revolutionized the treatment of CML. This paper focused on progress of drug therapy for CML.